4.7 Article

Three US Food and Drug Administration-approved therapies for chronic GVHD

Journal

BLOOD
Volume 139, Issue 11, Pages 1642-1645

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2021014448

Keywords

-

Categories

Funding

  1. Deutsche Forschungsgemeinschaft [SFB-1479, 441891347]
  2. National Institutes of Health [CA118953, CA236229]

Ask authors/readers for more resources

Chronic graft-versus-host disease (cGVHD) is a major immunologic complication of allogeneic hematopoietic cell transplantation, and current treatments often have severe side effects. In recent years, ibrutinib, belumosudil, and ruxolitinib have been approved by the US Food and Drug Administration for cGVHD and hold promise for future treatment.
Chronic graft-versus-host disease ( cGVHD) is a major immunologic complication of allogeneic hematopoietic cell transplantation. cGVHD involves multiple organs, reduces quality of life, and often requires prolonged therapy with glucocorticoids, causing severe side effects. After 4 decades of testing multiple therapeutic approaches, ibrutinib, belumosudil, and ruxolitinib were US Food and Drug Administration approved for cGVHD in the last 4 years. Here we put a spotlight on their mechanisms of action, studies that led to approval, and their future role in cGVHD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available